stockportfolio.pro
ACADIA Pharmaceuticals Inc. P/E Ratio 2009–2025
ACADIA Pharmaceuticals Inc. (ACAD) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth +8.7%/yr over 16 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 11.61 | -13.9% |
| FY 2024 | 13.49 | — |
| FY 2023 | — | — |
| FY 2022 | — | — |
| FY 2021 | — | — |
| FY 2020 | — | — |
| FY 2019 | — | — |
| FY 2018 | — | — |
| FY 2017 | — | — |
| FY 2016 | — | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
| FY 2010 | 3.08 | — |
| FY 2009 | — | — |
Source: ACADIA Pharmaceuticals Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for ACADIA Pharmaceuticals Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeACADIA Pharmaceuticals Inc. — frequently asked questions
What is ACADIA Pharmaceuticals Inc.'s price-to-earnings ratio?
ACADIA Pharmaceuticals Inc. (ACAD) reported price-to-earnings ratio of 11.61 for fiscal year 2025, per its SEC filings.
How has ACADIA Pharmaceuticals Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2009 and 2025, ACAD's price-to-earnings ratio grew at roughly 8.7% per year (compound annual rate), from 3.08 to 11.61.
Where does this data come from?
Figures are computed from ACADIA Pharmaceuticals Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.